Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22
The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect
ISRA Med
[5] The primary contraindication for hydroxocobalamin injection is a known hypersensitivity to hydroxocobalamin, cobalt, or any component of the formulation
The most common mild to moderate digestive side effects included: nausea constipation diarrhea vomiting indigestion No liver-related safety concerns were observed
US$ 26.71
US$ 20.10
US$ 26.28
US$ 26.39
US$ 27.05
US$ 23.75
US$ 25.49
